PMID- 36693142
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20230825
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 24
IP  - 4
DP  - 2023 Mar
TI  - Advances in the available pharmacotherapy for the management of acute coronary 
      syndromes in patients presenting without persistent ST-segment elevation.
PG  - 453-471
LID - 10.1080/14656566.2023.2171788 [doi]
AB  - INTRODUCTION: Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), 
      including non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable 
      angina, represent a leading cause of mortality worldwide, with important 
      socio-economic consequences. NSTEMI accounts for the majority of acute coronary 
      syndromes and usually develops on the background of a nonocclusive thrombus. We 
      searched for relevant literature in the field in PubMed and clinicaltrials.gov as 
      of July 2022. AREAS COVERED: A number of pharmacotherapies are currently 
      available for treatment and secondary prevention, mainly including 
      antithrombotic, lipid-lowering and anti-inflammatory drugs. Pretreatment with 
      aspirin, anticoagulant and statin therapy is of key importance in the 
      preprocedural phase, while pretreating with an oral P2Y(12) inhibitor is not 
      routinely indicated in patients undergoing early invasive management. For 
      patients undergoing percutaneous coronary revascularization, pharmacotherapy 
      essentially consists of antithrombotic drugs, which should be carefully selected. 
      Finally, antithrombotic, lipid-lowering and anti-inflammatory drugs are important 
      components of long-term secondary prevention after a NSTE-ACS. EXPERT OPINION: 
      This article reviews the evidence supporting recommendation on pharmacotherapy in 
      patients presenting with a NSTE-ACS. Several randomized clinical trials are still 
      ongoing and are expected to further inform scientific knowledge and clinical 
      practice, with the final aim to improve the treatment of NSTE-ACS patients.
FAU - Greco, Antonio
AU  - Greco A
AUID- ORCID: 0000-0003-2926-9428
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
FAU - Finocchiaro, Simone
AU  - Finocchiaro S
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida, United States.
FAU - Capodanno, Davide
AU  - Capodanno D
AUID- ORCID: 0000-0002-5156-7723
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230207
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Aspirin/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Lipids
MH  - *Non-ST Elevated Myocardial Infarction/drug therapy
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - antiplatelet agents
OT  - antithrombotic therapy
OT  - non-ST-segment elevation myocardial infarction
OT  - percutaneous coronary intervention
OT  - pharmacotherapy
OT  - unstable angina
EDAT- 2023/01/25 06:00
MHDA- 2023/03/29 06:05
CRDT- 2023/01/24 14:22
PHST- 2023/03/29 06:05 [medline]
PHST- 2023/01/25 06:00 [pubmed]
PHST- 2023/01/24 14:22 [entrez]
AID - 10.1080/14656566.2023.2171788 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2023 Mar;24(4):453-471. doi: 
      10.1080/14656566.2023.2171788. Epub 2023 Feb 7.